Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK716155 injections · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| albiglutide | ACTIVE_COMPARATOR | albiglutide injection |
| albiglutide placebo | PLACEBO_COMPARATOR | placebo injection |
| Group A | EXPERIMENTAL | In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen. |
| Group B | EXPERIMENTAL | In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen. |
| Group C | EXPERIMENTAL | In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen. |
| Group D | EXPERIMENTAL | In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm. |
| Group E | EXPERIMENTAL | In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg. |
| Group F | EXPERIMENTAL | In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen. |
| Group G | EXPERIMENTAL | In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm. |
| Group H | EXPERIMENTAL | In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg. |
| Name | Type | Description |
|---|---|---|
| GSK716155 subcutaneous injections | DRUG | albiglutide subcutaneous injection |
| placebo injection | BIOLOGICAL | placebo injection |
Inclusion criteria: * Subjects must have type 2 diabetes mellitus that has been diagnosed for at least three months. * Must be taking either (1) no medication for their diabetes or (2) taking metformin, a sulfonylurea, or metformin and a sulfonylurea. * Subjects must be willing to wash-out of these...
GSK716155 injections are used for the treatment of Type 2 Diabetes Mellitus. The drug is being developed by GSK plc and is currently in Phase 2 clinical development. It is an investigational small molecule being studied for its effects on blood sugar control in patients with this condition.
GSK716155 is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of Type 2 Diabetes Mellitus.
GSK716155 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for its potential use in treating Type 2 Diabetes Mellitus.
GSK716155 has been studied in two completed clinical trials. NCT00354536 was a Phase 2 in-patient study in 60 patients with Type 2 Diabetes Mellitus in the United States. NCT00394030 was a Phase 1 injection site study in 63 patients and healthy volunteers. Both trials are completed.
No alternative names for GSK716155 have been identified. The drug is known by its development code GSK716155 and is being studied as an injection for the treatment of Type 2 Diabetes Mellitus. It is an investigational small molecule developed by GSK plc.